Efgartigimod in the treatment of Guillain–Barré syndrome
Efgartigimod in the treatment of Guillain–Barré syndrome
About this item
Full title
Author / Creator
Zhang, Huiqiu , Ma, Jing , Feng, Yingna , Ma, Hui , Liu, Dan , Pang, Xiaomin , Chang, Xueli , Zhao, Rongjuan , Wang, Juan , Guo, Junhong and Zhang, Wei
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Background
Guillain–Barré Syndrome (GBS) is caused by immunoglobulin G (IgG) autoantibodies. Efgartigimod, a human IgG antibody Fc fragment that acts as a natural ligand for the FcRn, can increase IgG degradation, which thus may be a promising therapeutic drug for GBS.
Case presentation
The two patients presented with postinfectious and ac...
Alternative Titles
Full title
Efgartigimod in the treatment of Guillain–Barré syndrome
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3061504473
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3061504473
Other Identifiers
ISSN
0340-5354,1432-1459
E-ISSN
1432-1459
DOI
10.1007/s00415-024-12321-4
